Biotech

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report and Accounts

🕔2/25/2020 12:19:48 PM

Anatara Lifesciences Ltd (ASX:ANR) present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the half-year ended 31 December 2019.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore Interview

🕔2/21/2020 8:39:05 PM

Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore was recently interviewed by Stockhead, for its "90 Seconds With" interview series. Steve provided an overview of the Company's key milestones for the next 12 months.

Read Full Article

Regeneus Ltd (ASX:RGS) Appendix 4C - Quarterly

🕔1/31/2020 9:48:10 AM

Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its quarterly cashflow report and review of operational activities for the period ending 31 December 2019 (Q2 FY20).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Preclinical Program Summary

🕔1/22/2020 11:23:32 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide a summary of the preclinical studies conducted to date for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Cashflow

🕔1/15/2020 8:40:10 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2019. The Company's cash plus term deposits at the end of the quarter stood at $4.30m

Read Full Article

Regeneus Ltd (ASX:RGS) AGC Agreement Termination Paves Way for Commercial Partner

🕔12/20/2019 10:33:02 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has come to a mutual agreement with Japan-based manufacturer AGC Inc to terminate their exclusive manufacturing licence and joint venture agreement.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Finalises Draft Protocol for IBS Clinical Trial

🕔12/20/2019 8:21:26 AM

Anatara Lifesciences (ASX:ANR) is pleased to provide an update on the protocol for its clinical trial in irritable bowel syndrome (IBS) for its GaRP dietary supplement.

Read Full Article